Drug Combination Details
| General Information of the Combination (ID: C52062) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | ML1 | CVCL_0436 | Adult acute myeloid leukemia | Homo sapiens | ||
| K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
| Raji | CVCL_0511 | EBV-related Burkitt lymphoma | Homo sapiens | |||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | |||
| COLO 205 | CVCL_0218 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br J Cancer. 2006 Feb 13;94(3):398-406. | |||
